000			03064cam a2200349 a 4500
003			EG-GiCUC
005			20250223032752.0
008			210624s2021 ua d f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.11.07.M.Sc.2021.Ya.E
100	0		_aYasmin Mohsen Abdelrazek Mohamed
245	1	0	_aExpression of NKp30 in de novo acute myeloid leukemia patients and its Impact on prognosis / _cYasmin Mohsen Abdelrazek Mohamed ; Supervised Dina Mohamed Rasheed Bahgat , Maha Saleh Madbouly Ibrahim , Aliaa Sayed Eldash
246	1	5	_aفى مرض سرطان الدم النخاعى الحاد حديثى التشخيص و تاثيره على تطور المرض NKp30دور تعبيرالمستقبلات المناعية
260			_aCairo : _bYasmin Mohsen Abdelrazek Mohamed , _c2021
300			_a150 P . : _bcharts ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology
520			_aAcute myeloid leukemia (AML) is a heterogeneous group of diseases characterized by uncontrolled proliferation of hematopoietic progenitor cells with arrest of maturation and disruption of normal hematopoiesis. NKp30 is a protein found on the surface of human natural killer (NK) cells. The ligand of NKp30 is called B7-H6. NKp30 belongs to a group of molecules called Natural Cytotoxicity Receptors (NCRs). When NKp30 on a NK cell binds to B7-H6 on a human tumor cell, the NK cell is triggered to become cytotoxic and exert antitumor effects. We studied the expression of NKp30 on 35 patients diagnosed with AML and 30 controls, to evaluate the impact of its expression on outcome and its possible association with other known prognostic markers. Flowcytometric analysis was performed using direct staining method by monoclonal antibody CD337 (NKp30) gated on NK cells (CD3-/56+).The expression of NKp30 on NK cells was found to be significantly lower in AML group compared to the control group, with p-value 0.042 for the NKp30% and p-value <0.001 for the rMFI. ROC analysis was used to predict cut off values for NKp30 expression as a marker for stratifying AML patients. NKp30% expression cut off was chosen at 11.155%. rMFI expression cut off was chosen at 4.13, with sensitivity (62.9% , 85.7%) and specificity (53.3% ,66.7%) respectively. Nkp30% significantly correlated with overall survival (P=0.030); where patients with high expression of NKp30% had longer OS time while patients with low expression of NKp30 % were more prone to earlier death than those with high marker expression (HR:2.580)
530			_aIssued also as CD
653		4	_aAML
653		4	_aNKp30
653		4	_aOverall survival
700	0		_aAliaa Sayed Eldash , _eSupervising
700	0		_aDina Mohamed Rasheed Bahgat , _eSupervising
700	0		_aMaha Saleh Madbouly Ibrahim , _eSupervising
856			_uhttp://172.23.153.220/th.pdf
905			_aAmira _eCataloger
905			_aNazla _eRevisor
942			_2ddc _cTH
999			_c81381 _d81381